GSK, Vir Bio start study of COVID-19 antibody therapy
The Phase II/III COMET-ICE study will assess safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19
Read More
Tag: Vir
GSK links with Vir Biotechnology to find coronavirus solutions
GSK has bought a $250 million stake in the firm
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
